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Salvage chemotherapy for recurrent 
primary brain tumors in children 
Jan van Eys, PhD, MD, Tallie Z. Baram, MD, PhD, Ayten Cangir, MD, 
Janet  M. Bruner, MD, and J. Martinez-Prieto, MD 
From the Departments of Pediatrics, Neurooncology, and Pathology, The University of Texas 
M, D. Anderson Cancer Center at Houston 
Sixty consecutive evaluable children with recurrent primary tumors of the 
central nervous system were treated with a regimen of vincristine, nitrogen 
mustard, procarbazine, and prednisone over a 12-year period. Tumor types 
included medulloblastoma (19), brain-stem glioma (16), astrocytoma (13), and 
a miscellaneous gl ioma (12). Responses and sustained survivals were 
achieved. Responses were highly dependent on tumor type. Disease progres- 
sion was halted in 73% of the children with medulloblastoma, and three have 
survived in complete remission for more than 10 years from the start of therapy 
with vincristine, nitrogen mustard, procarbazine, and prednisone. Two of four 
patients with anaplastic glioma, are long-term survivors. In contrast, less than 
one third of children with brain-stem gliomas responded. Toxicity consisted 
mainly of neutropenia, thrombocytopenia, infections, and rarely a procarba- 
zine rash. (J PEDIAI'R 1988;113:601-6) 
Therapy for recurrent brain tumors in children remains 
unsatisfactory; most die of their disease regardless of 
therapy, l We have repbrted on the responsiveness of
recurrent brain tumors in children to chemotherapy with 
vincristine, nitrogen mustard, procarbazine, and predni- 
sone. 2A later prospective randomized trial confirmed the 
contribution of nitrogen mustard, although because of the 
greater toxicity, no difference in survival was observed 
between the two treatment regimens. 3 Since then we have 
extended the use of MOPP to primary therapy for infants 
with brain tumors in whom radiotherapy may result in 
devastating sequelae. 4 The efficacy of MOPP as primary 
therapy for infants with medulloblastomas after surgery 
has been established. 5 
We now report on our experience of more than 10 years 
with MOPP as salvage therapy for recurrent brain tumors 
in children. Our experience allows assessment of the 
comparative responsiveness of different umor types and 
shows the durability of the response in some children with 
medulloblastoma. A preliminary report has appeared. ~ 
Reprint requests: Jan van Eys, PhD, MD, Department ofPediat- 
rics, The University of Texas M.D. Anderson Hospital and Tumor 
Institute, 1515 Holcombe Blvd., Houston, TX 77030. 
METHODS 
Patients. Sixty-five children with a median age of 6 
years (range, 1 to 16 years) were treated with MOPP for 
recurrent brain tumors. Sixty patients were eligible for 
evaluation; the other five patients were excluded because 1
died before completion of the first MOPP course, the 
! 
CT Computed tomography [ 
MOPP Nitrogen mustard, vincristine, procarbazine 
and prednisone 
records of two others were not available, and two patients 
received intrathecal methotrexate concurrently with 
MOPP. All patients had failed to respond to primary 
therapy consisting of either surgery, radiation, or both. 
Thirteen patients had also failed to respond to a previous 
chemotherapy regimen for tumor recurrence. Previous 
chemotherapy consisted of one or more of the following 
drugs: vincristine, lomustine, methotrexate (systemic, 
intrathecal, or both), etoposide, and cisplatin. 
The distribution of tumor type6 and patients' ages and 
gender are listed in Table I. Tissue diagnoses were avail- 
able for all patients with medull0blastomas but for only 5 
of 16 of those with brain-stem gliomas. Among the group 
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Fig. t. Meier-Kaplan curve for survival from the time of diagno- 
sis in patients with medulloblastomas (square), gliomas (circle), 
brain-stem gliomas (diamond), and miscellaneous tumors (star). 
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Fig. 2. Meier-Kaplan curve for survival from initiation of 
MOPP therapy in patients with medulloblastomas (square), glio- 
mas (circle), brain-stem gliomas (diamond), and miscellaneous 
tumors (star). 
Tab le  I. Characteristics of patients treated with salvage MOPP regimen 
Tumor type No. 
Gender  
Mean age  at diagnosis 
(range, yr) M F 
Medulloblastoma 19 
Brain-stem glioma 16 
Astrocytoma 13 
Glioblastoma mnltiforme 4 
Mixed glioma, anaplastic 4 
Pilocytic/ganglioglioma/unknown 5 
Miscellaneous 12 
Ependymoma 4 
Primitive neuroectodermal 4 
One case each of meningeal sarcoma, 4 
malignant meningioma, embryonal 
carcinoma, choroid plexus 
carcinoma 
7 (11/12-12) 16 3 
7 (21/2-3½) 6 10 
11 (7-15) 7 6 
11 (7-13½) 3 1 
lO (7-12) 1 3 
13 (12-15) 3 2 
5 (9/12-15) 4 8 
8 (3-15) I 3 
4 (8/12-12) 3 1 
6 (9/12-13) 0 4 
with astrocytomas, five patients had glioblastoma multi- 
forme (World Health Organization criteria), 7 two had 
anaplastic astrocytomas, two had mixed gliomas with an 
aggressive astrocytic omponent, wo had pilocytic tumors, 
and one had a ganglioglioma. In two cases of aggressive 
thalamic lesions, no tissue specimens were available. The 
group of miscellaneous tumors included four ependymo- 
mas (one with ependymoblastoma features), four supra- 
tentorial primitive neuroectodermal tumors, two of the 
pineal region, one meningeal sarcoma, one malignant 
meningioma, one choroid plexus carcinoma, and one 
embryonal carcinoma. Two patients with medulloblasto- 
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Table II. MOPP regimen*: Twenty-eight-day c cles for 
2 years 
Dosage 
Drug (rng/m 2) Cycl e 
Nitrogen mustard 6 Days 1, 8 
Vincristin e 1.4 Days I, 8 
Procarbazine 100 Days 1-I0 
Prednisone 40 Days 1-10, 
then tapered 
*Dose modification for hematopoietie toxicity: Leukocytes, 3000 to 
4000/mm3: 50% of procarbazine and nitrogen mustard. Platelets 
>100,000/mm3 and leukocytes, 2000 to 3000/mm3: 25% of procarbazine 
and nitrogen mustard. Leukocytes, 1000 to 2000/mm3: noprocarbazine 
or nitrogen mustard and 50% of vincristine. Platelets, 50,000 to 
100,000Jmm3: 100% of vincristine and 25% of nitrogen mustard, no 
procarbazine. Platelets <50,000/mm3: no therapy. 
mas had extraneural metastases, and seven had malignant 
cells in the Subarachnoid Space. Leptomeningeal 'spread 
was also documented in two patients with ependymoma 
and in two with primitive neuroectodermal tumors. 
Treatment. Before they began MOPP therapy, all 
Patients had complete clinical evaluations that included 
functional status and neuro!ogic examination. The need for 
steroids and the dosages given were recorded in each case. 
If dexamethasone (Decadron) was initially necessary, 
prednisone was omitted. Each patient had a computerized 
axial tomography scan of the brain. Cerebrospinal f uid 
was examined for malignant cells whenever required and 
permitted bY neurologic status. Laboratory examinations 
include d complete blood cell counts plus hepatic and renal 
function tests. 
All patients were treated with the standard MOPP 
chemotherapy regimen every 28 days. The regimen was 
modifie d for myelosuppression (Table II). Treatment was 
continued for 2 years or until disease progression devel- 
oped, whichever occurred first. 
Patients were followed (including full neurologic exam- 
ination and CT scans of the brain) at regular intervals, 
usually every 3 months, or whenever symptoms recurred. 
Blood counts were performed at weekly intervals early in 
the course of treatment and then twice monthly. 
The Kaplan-Meier method was used to generate actuar- 
ial curves of Survival from diagnosis, survival from initia- 
tion of MOPP therapy, and time to tumor progression 
from start of the therapy. 
Response was defined according to the criteria recom- 
mended by the American Cancer Society workshop at 
Niagara Falls, 7 which are different from those used previ- 
ouslY by us. Complete response is absence of tumor on CT 
scan and in cerebrospinal fluid studies when applicable; 
partial response is CT evidence of 50% tumor mass 
o.g. 
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Fig. 3. Time to tumor progression on MOPP therapy for 
patients wit h medulloblastomas (square), 'gliomas (circle), brain- 
stem gliomas (diamond), and miscellaneous tumors (star). 
regression (measured as sum of perpendicular diameters). 
Stable disease or improvement is defined by tumor mass 
reduction of <50% as already defined. Progressive disease 
is an increase in tumor mas by >25%. 
These radiographic riteria are not useful for evalua- 
tions of brain-stem glioma. 7 Therefore for this patient 
group, we used a combination of neurol0gi c and function 
status, steroid dependence, and CT appearance/ 
RESULTS 
Responses of patients with various tumor types to 
MOPP therapy are shown in Table ili. Survival from 
diagnosis and initiation of therapy and time to tumor 
progression are depicted in Figs. 1 to 5. Disease progres- 
sion was halted in 14 of19 patients with medulloblasto- 
mas. Mean time to tumor progression i  13 patients wile 
had a relapse was 6 months (Fig. 3); yet of 12 patients 
followed up for more than 5 years from initiation of MOPP 
therapy, three have survived in complete c!inical remission 
(12, 10, and t9 years, ~respetgively) (Fig. 2). MOPP 
therapy eliminated malignant cells in only one of seven 
patients with medulloblastoma with leptomeningeal spread 
and positive cytologic findings~ Of cerebrospinal fluid. In 
two patients with extraneural metastases, a femoral lesion 
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Fig, 4. Survival from the time of diagnosis of patients with 
glioblastomas (circle), other astrocytomas (diamond), and the 
combined group (square). 
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Fig. 5- Time to tumor progression of patients witb glioblastomas 
(circle), other astr0cytomas (diamond), and the combined group 
(square). 
Table III. Response rates of brain-tumors to salvage MOPP 
Complete Part lal  Stable All Progressive 
Tumor type No. remission response disease responses disease 
Medulloblastoma 19 I 3 10 14 5 
Brain-stem glio- 16 0 3 2 5 11 
ma 
Astrocytomas 13 2 2 7 11 2 
Miscellaneous 12 0 2 5 7 5 
Total 60 3 10 24 37 23 
was markedly reduced in size by MOPP, whereas a chest 
mass progressed uring treatment. 
Mean time to tumor progression in four Patients with 
glioblastomas was 71/2 months (Fig. 5); survival from 
diagnosis averaged 26 months (Fig. 4). Patients with 
anaplastic astr0cytomas or mixed gliomas wit h an aggres: 
sive astrocytic omponent fared better (Figs: 4 and 5) and 
two are long-term survivors (81/2 and 4 years from therapy 
onset, respectively). One patient died 8 months after 
MOPP initiation, and a fourth has had a partial response 
and is currently receiving therapy. Among patients with 
lower-grade gliomas, those patients with recurrent' gangli- 
og!iomas and pilocytic astrocytomas re alive 31/2 and 4 
years, respectively, from the beginning of therapy, but the 
two patients with unbiopsied thalamic lesions died 16 
months after diagnosis (Figs. 4 and 5). 
Response and survival of patients with brain-stem glio- 
mas were poor. Mean time t0 progression was 31/2 months, 
and 0nly two patients urvived (Figs. 1 to 3). 
Of the four patient s with ependymomas in the miscella- 
neous group, one has completed therapy and is in remis- 
sion, and the others died within 6 months of MOPP 
initiation. For the patients with a variety'of other lesions, 
the disease was uniformly and rapidly fatal, (Table III and 
Figs. 1 to 3). 
The toxicity of the MOPP regimen is outlined in Table 
IV, Bone marrow suppression, mainly neutropenia, was 
common and required dose adjustment (Table II). Most 
Volume 113 MOPP for recurrent brain tumors 605 
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infections, such as otitis media, were mild, but two deaths 
occurred: one as a result of Pneumo'cystic carinii pneumo- 
nia and one as a result of a cerebral aspergilloma. 
D ISCUSSION 
The prognosis for all patients with recurrent brain 
tumors remains poor. For example, in the largest reported 
series of 120 medulloblastomas, 82% of 35 recurrent 
tumors resulted in death within a year of recurrence? 
Therefore progressively more novel and toxic therapy 
regimens have been advocated? In general, however, 
results have depended more on the biologic properties of 
the specific tumor than on the chemotherapeutic agents. 
At our institution, the MOPP regimen has been front- 
line therapy for recurrent brain tumors in children. The 
rationale is discussed extensively elsewhere?. 5 The results 
confirm the marked differences in the susceptibility of 
various brain tumors to chemotherapy. At one end of the 
response spectrum are brain-stem gliomas, whose natural 
course has been minimally affected by chemotherapy~,8; 
our results are no exception. Similarly, the survival of our 
four patients with glioblastomas i no better than that 
reported in other series. ~,9 Among four children with 
anaplastic gliomas, the long-term survival of two (8 and 
four years) and the partial response of a third patient attest 
to the value of MOPP for this tumor type. Moreover, in 
more than 70% of patients with other aggressive recurrent 
tumors such as medulloblastoma, MOPP arrested isease 
progression. According to new stringent radiologic rite- 
ria, 7 most patients in our series fall into the stable disease 
category, and yet a residual tumor mass shown on a CT 
scan with <50% reduction in size may indicate an inactive 
tumor and is compatible with long-term survival. Thus 
three of six patients with medulloblastomas foliowed Up for 
more than 10 years are m complete clinical remission with 
unchanged residual esions on CT scan. Many patients in 
this series were enrolled before the routine use of magnetic 
resonance imaging. This diagnostic method may help 
resolve the dilemma of response definition. 
Our results compare favorably with those of Other large 
series. Crafts et al. l~ used procarbazine, lomustine, aiad 
vincristine in 17 children With recurrent medulloblastomas. 
Using less stringent response criteria, they reported a 62% 
response rate and a 31% Stable disease rate. Mean time to 
tumor progression was 45 weeks, and there were no 
long-term survivors. ~~ Of eight patients H Who received 
vincristine, carmustine, dexamethasone, and intrathecal s 
well as intravenous methotrexate, one has survived for 5 
years and two others were in remission at 9 and 17 months, 
respectively, from the time that therapy was initiated. The 
only other study that used the American Cancer Society 
response criteria ~ e~,aluated vineristine and cyelophospha- 
mide for the treatment of recurrent medulloblastomas. 
Table IV. Toxic reactions to MOPP regimen during 307 
fully evaluable courses (71% of 398 courses 
administered) 
No. of 
courses in 
which condition % of fully 
Condition was present evaiuable courses 
Total leukocytes 175 57 
<3000/mm 3 
Platelets 35 11.4 
< 100,000/mm ~ 
Infections 33 10.7 
Procarbazine rash 2 0.6 
Courses of 145 47 
reduced 
dosages 
Fourteen of 16 patients manifested some response (com- 
plete, partial, or stable disease), and yet there were no 
long-term Survivors. ~2 
Preliminary results of the so-called eight-in-one r gimen 
for recurrent brain tumors (including medulloblaStoma) 
were recently published. ~3 A 70% response rate has been 
claimecl, ~ind yet patien t number, response criteria, surviv- 
al, time tO progression, or toxicity were not discussed/3 
Toxicity of the MOPP regimen, which consisted mainly 
of neutropenia, resulted in dose reduction in 47% of 
evaluable courses, but the reductions allowed Uninterrupt- 
ed therapy: This compares favorably with the reported 
severe bone marrow toxicity, ~~ which required significant 
dosage reductions for 15 of 16 patients. 
Thus MOPP emerges as a fairly tolerable multiagent 
regimen for recurrent brain tumors with significanl~ sal- 
vage potential. This Chemotherapy for recurrent medullo- 
blastomas and astrocytomas (anaplastic and low-grade) 
resulted in a significant number of long-term survivors. 
These results and the established efficacy of MOPP 
chemotherapy, combined with surgery, as primary treat- 
ment for brain tumors in infants, 4 especially those with 
medul!oblastomas, 5 nd the recent promising results with 
MOPP for adjuvant herapy for the same tumor, call fo? 
further study of MOPP in the treatment of brain tumors in 
children. 
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